Figure 7.
KLRB1 overexpression was correlated with the OS in cancer patients on immunotherapy. (A) Anti-PD-1; (B) Pembrolizumab; (C) Anti-PD-L1; (D) Atezolizumab; (E) Ipilimumab; (F) Pretreatment; (G) Ontreatment. Abbreviation: OS: overall survival.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.